In this Issue
From monoclonal antibodies to non-invasive neuromodulation, new classes of therapeutic interventions for headache and migraine come with great expectations.
New AAN President sees collaboration and wellness as integral to the future of the specialty.
As a new age in headache medicine is set to begin, it is incumbent upon neurologists to become better familiarized with and explore the implications of monoclonal antibodies in patient care.
By Peter McAllister, MD
Neuromodulation devices represent a unique opportunity to patients for effective treatment of migraine in a cost-effective fashion with no significant side effects.
By Stewart J. Tepper, MD
By Mark J. Burish, MD, PhD
Assessing orientation offers a viable means of concussion screening and measuring the neurological impact of head injuries.